Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Common Equity: 2009-2024

Historic Common Equity for Iovance Biotherapeutics (IOVA) over the last 11 years, with Dec 2024 value amounting to $710.4 million.

  • Iovance Biotherapeutics' Common Equity fell 9.20% to $702.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $702.3 million, marking a year-over-year decrease of 9.20%. This contributed to the annual value of $710.4 million for FY2024, which is 21.52% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Common Equity stood at $710.4 million, which was up 21.52% from $584.6 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Common Equity registered a high of $710.4 million during FY2024, and its lowest value of $584.6 million during FY2023.
  • For the 2-year period, Iovance Biotherapeutics' Common Equity averaged around $647.5 million, with its median value being $647.5 million (2023).
  • Data for Iovance Biotherapeutics' Common Equity shows a peak YoY rose of 21.52% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Common Equity (Yearly) stood at $584.6 million in 2023, then grew by 21.52% to $710.4 million in 2024.